Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study

  • Original Article
  • Published:
Diabetology International Aims and scope Submit manuscript

Abstract

Objective

To examine long-term efficacy/safety of ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, added to ongoing insulin therapy in Japanese patients with type 2 diabetes.

Methods

We conducted a 36-week, open-label extension of ipragliflozin therapy following a 16-week, randomized, placebo-controlled, double-blind period (treatment periods II and I, respectively). Prior to the open-label period, patients taking insulin with/without a dipeptidyl peptidase-4 (DPP-4) inhibitor were randomized to receive placebo or 50 mg once-daily ipragliflozin. Oral antidiabetic drugs other than DPP-4 inhibitors were discontinued 4 weeks before screening. Following treatment period I, all patients received open-label ipragliflozin 50 mg, with the possibility of a dose increase to 100 mg at week 24 if HbA1c was ≥ 7.0% at week 20. Efficacy endpoints were changes in HbA1c, fasting plasma glucose (FPG), self-monitored blood glucose, bodyweight, and metabolic hormones. Drug-related treatment-emergent adverse events (TEAEs) were monitored for safety.

Results

Of 175 patients randomized to ipragliflozin, 168 entered treatment period II, 121 (69%) of whom completed this period. The mean ± standard deviation changes in HbA1c, FPG, and bodyweight from baseline (start of treatment period I) to the end of treatment were − 0.83 ± 0.72%, − 31.5 ± 41.2 mg/dL, and − 1.34 ± 1.80 kg, respectively. Between weeks 8 and 32, HbA1c was lower in patients taking a DPP-4 inhibitor than in those without. The most common drug-related TEAE was hypoglycemia; no drug-related TEAEs not already reported for ipragliflozin were observed.

Conclusions

Ipragliflozin was well tolerated, effective, and reduced bodyweight over a period of 52 weeks in patients treated with insulin with/without a DPP-4 inhibitor.

Clinicaltrials.gov identifier

NCT02175784

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications. 2015;29:295–301.

    Article  PubMed  Google Scholar 

  2. Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2016;32:478–96.

    Article  CAS  PubMed  Google Scholar 

  3. Wu T, Betty B, Downie M, et al. Practical guidance on the use of premix insulin analogs in initiating, intensifying, or switching insulin regimens in type 2 diabetes. Diabetes Ther. 2015;6:273–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ross SA, Tildesley HD, Ashkenas J. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes. Curr Med Res Opin. 2011;27(Suppl 3):13–20.

    Article  CAS  PubMed  Google Scholar 

  5. Monami M, Ragghianti B, Zannoni S, et al. Identification of predictors of response to basal insulin and DPP-4 inhibitors in patients with type 2 diabetes failing to other therapies. Acta Diabetol. 2016;53:35–40.

    Article  CAS  PubMed  Google Scholar 

  6. Kashiwagi A, Kazuta K, Goto K, et al. Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2015;17:304–8.

    Article  CAS  PubMed  Google Scholar 

  7. Kashiwagi A, Kazuta K, Yoshida S, et al. Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2014;5:382–91.

    Article  CAS  PubMed  Google Scholar 

  8. Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab. 2015;17:152–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ishihara H, Yamaguchi S, Nakao I, et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study. Diabetes Obes Metab. 2016;18:1207–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Liu XY, Zhang N, Chen R, et al. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. J Diabetes Complications. 2015;29:1295–303.

    Article  PubMed  Google Scholar 

  11. Yamauchi T, Kadowaki T. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases. Int J Obes (Lond). 2008;32(Suppl 7):S13–8.

    Article  CAS  Google Scholar 

  12. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wilding JP, Woo V, Rohwedder K, et al. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16:124–36.

    Article  CAS  PubMed  Google Scholar 

  14. Inagaki N, Harashima S, Maruyama N, et al. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2016;15:89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Suzuki K, Mitsuma Y, Sato T, et al. Comparison of combined tofogliflozin and glargine, tofogliflozin added to insulin, and insulin dose-increase therapy in uncontrolled type 2 diabetes. J Clin Med Res. 2016;8:805–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Araki E, Onishi Y, Asano M, et al. Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: results of the interim analysis of 16-week double-blind treatment period. J Diabetes Investig. 2016;7:555–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Araki E, Onishi Y, Asano M, et al. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial. Diabetes Obes Metab. 2016;19:562–70.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank all of the investigators involved in this trial, as well as Nicholas Smith, PhD, and William Ng, MB, BS, PhD, of Edanz Medical Writing for providing medical writing services.

Funding

This study was sponsored by Astellas Pharma Inc. Medical writing and editorial support was funded by Astellas Pharma Inc. and provided by Dr. Nicholas D. Smith and Dr. William Ng (Edanz Medical Writing) and Elsevier/ELMCOM™.

Author information

Authors and Affiliations

  1. Division of Diabetes and Metabolic Diseases, Nihon University School of Medicine, 30-1 Oyaguchikami-cho, Itabashi-ku, Tokyo, 173-8610, Japan

    Hisamitsu Ishihara

  2. Astellas Pharma Inc., Tokyo, Japan

    Susumu Yamaguchi, Ikko Nakao, Seitaro Asahina & Taishi Sakatani

Authors
  1. Hisamitsu Ishihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susumu Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ikko Nakao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Seitaro Asahina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Taishi Sakatani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HI, SA, and TS contributed to study design, data analysis, and writing of the manuscript; SY and IN contributed to study design, study conduct, data collection and analysis, and writing of the manuscript.

Corresponding author

Correspondence to Hisamitsu Ishihara.

Ethics declarations

Conflict of interests

HI has served on the scientific advisory board of Astellas Pharma Inc.; received lecture or consulting fees from Astellas Pharma Inc., MSD, Sanofi, Mitsubishi Tanabe Pharma, Boehringer Ingelheim Japan, and Novartis Pharma; and received grants/research support from Astellas Pharma Inc., Ono Pharmaceutical, Boehringer Ingelheim Japan, AstraZeneca, Sanofi, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Daiichi-Sankyo, Novo Nordisk Pharma, Kyowa Hakko Kirin, and MSD. SY, IN, SA, and TS are employees of Astellas Pharma Inc., Japan.

Ethical standards

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.

Informed consent

Informed consent or substitute for it was obtained from all patients for being included in the study. The study was approved by the institutional review board at each participating site.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PPTX 86 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ishihara, H., Yamaguchi, S., Nakao, I. et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a 36-week, open-label extension of a 16-week, randomized, placebo-controlled, double-blind study. Diabetol Int 10, 37–50 (2019). https://doi.org/10.1007/s13340-018-0359-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13340-018-0359-x

Keywords

Search

Navigation